Equities

Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS

ONCSM.E:IST

Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS

Actions
Health CareMedical Equipment and Services
  • Price (TRY)141.80
  • Today's Change-3.00 / -2.07%
  • Shares traded6.08m
  • 1 Year change-29.80%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 16:09 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of TRY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments59195.77
Total Receivables, Net567934
Total Inventory788833
Prepaid expenses3.196.856.48
Other current assets, total06.285.74
Total current assets19519985
Property, plant & equipment, net11813739
Goodwill, net------
Intangibles, net4.853.391.88
Long term investments1.851.05--
Note receivable - long term0.120.210.10
Other long term assets------
Total assets338350130
LIABILITIES
Accounts payable172611
Accrued expenses7.546.223.84
Notes payable/short-term debt57120.14
Current portion long-term debt/capital leases2.717.019.25
Other current liabilities, total6.384520
Total current liabilities919644
Total long term debt1.343.614.60
Total debt612314
Deferred income tax11231.55
Minority interest000
Other liabilities, total3.612.840.54
Total liabilities10712651
SHAREHOLDERS EQUITY
Common stock242020
Additional paid-in capital960--
Retained earnings (accumulated deficit)11220459
Treasury stock - common------
Unrealized gain (loss)----0
Other equity, total------
Total equity23222479
Total liabilities & shareholders' equity338350130
Total common shares outstanding242424
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.